AstraZeneca Results Presentation Deck

9 Alexion acquisition closed Integration and synergies next & AstraZeneca Acquisition closed on 21 July 2021 Alexion delisted and the AstraZeneca share base expanded Strong strategic rationale - accelerate expansion into immunology and rare diseases further-sustained, industry-leading ALEXION double-digit revenue growth - - improved profitability and strengthened cash flow AstraZeneca Rare Diseases B

View entire presentation